Skip to main content

Table 2 Pharmacokinetic parameters after a single dose of CAT-354 (PK population)

From: A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma

 

CAT-354

 

1 mg/kg (n = 8)

5 mg/kg (n = 8)

10 mg/kg (n = 3)

Cmax (μg/mL)

30.3 (5.2)

157 (34.5)

306 (31.4)

AUC(0-t) (μg.day/mL)

300 (42.0)

1691 (303)

3106 (719)

AUC(0-inf) (μg.day/mL)

428 (83.3)

2314 (393)

3861 (662)

t1/2 (days)

16.6 (2.7)

16.1 (3.6)

11.8 (1.9)

CL* (mL/day/kg)

2.41 (0.5)

2.23 (0.5)

2.64 (0.4)

Vd (mL/kg)

56.7 (8.0)

51.0 (10.4)

44.0 (0.8)

  1. Note: Values are arithmetic mean (SD) after dose 1.
  2. *Corrected for body weight
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us